The current financial score of Arcus Biosciences Inc is 7.23. Its financial status is weak, and its operating efficiency is average.
The current valuation score of Arcus Biosciences Inc is 7.38. Its current P/E ratio is -7.96, which is -79.62% below the recent high of -1.62 and -25.08% above the recent low of -9.96.
The current earnings forecast score of Arcus Biosciences Inc is 8.00. The average price target is 38.75, with a high of 47.00 and a low of 23.00.
The current price momentum score of Arcus Biosciences Inc is 5.75. Currently, the stock price is trading between the resistance level at 30.11 and the support level at 21.84, making it suitable for range-bound swing trading.
The current institutional shareholding score of Arcus Biosciences Inc is 7.00. The latest institutional shareholding proportion is 82.11%, representing a quarter-over-quarter increase of 34.03%. The largest institutional shareholder is Ken Fisher, holding a total of 2.14M shares, representing 0.02% of shares outstanding, with 23.85% increase in holdings.
The current risk assessment score of Arcus Biosciences Inc is 5.75. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.